Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits
- PMID: 37774696
- DOI: 10.1016/j.ccell.2023.08.005
Genetically informed therapy for lymphoma: the discomfiting benefit of lumping splits
Abstract
Zhang et al. report a randomized phase 2 trial for diffuse large B cell lymphoma (DLBCL) that compared standard of care (R-CHOP) to R-CHOP combined with one of 5 agents matched to an individual lymphoma's genetics. Overall, the matching strategy significantly outperformed R-CHOP, laying the foundation for a paradigm-shifting phase 3 trial.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.C.P. received consulting fees from Merck, Astra Zeneca, and Kymera and research support from Prelude Therapeutics. D.M.W. is an employee of Merck and Co., owns equity in Merck and Co.; Bantam; Ajax; and Travera; received consulting fees from Astra Zeneca; Secura; Novartis; and Roche/Genentech; and received research support from Daiichi Sankyo; Astra Zeneca; Verastem; Abbvie; Novartis; Abcura; and Surface Oncology.
Comment on
-
Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial.Cancer Cell. 2023 Oct 9;41(10):1705-1716.e5. doi: 10.1016/j.ccell.2023.09.004. Epub 2023 Sep 28. Cancer Cell. 2023. PMID: 37774697
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials